Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Group 1 - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of Unicycive Therapeutics, Inc. [1] - A federal securities lawsuit alleges that insiders at Unicycive Therapeutics misrepresented the company's ability to meet FDA manufacturing compliance requirements and overstated the regulatory prospects of the OLC NDA [2] - Public statements made by Unicycive Therapeutics were claimed to be materially false and misleading at all relevant times due to these misrepresentations [2] Group 2 - Shareholders who purchased UNCY shares prior to March 29, 2024, are encouraged to contact Kuehn Law for potential legal action, as there may be limited time to enforce their rights [3] - Kuehn Law covers all case costs and does not charge its investor clients, emphasizing the importance of shareholder participation in maintaining market integrity [4]